Fluoroquinolones in the management of community-acquired pneumonia

Timothy E Albertson, N. C. Dean, A. A. El Solh, M. H. Gotfried, C. Kaplan, M. S. Niederman

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Aims: Review of the current guidelines for the use of respiratory fluoroquinolones in the management of community-acquired pneumonia (CAP). Methods: Data were collected from recent clinical trials on fluoroquinolone therapy in patients with CAP and from updated recommendations of antimicrobial therapy in managing CAP, with a focus on current North American guidelines. Results: Randomised clinical trials of respiratory fluoroquinones (moxifloxacin, levofloxacin and gemifloxacin) in the treatment of CAP were identified and analysed. The bacteriology of CAP, and susceptibility rates, resistance rates and pharmacokinetic and pharmacodynamic properties of fluoroquinolones against causative pathogens in CAP, and adverse event profiles of these agents were described. Respiratory fluoroquinones have broad-spectrum antibacterial activities against common causative pathogens in CAP and provide an important treatment option as monotherapy for outpatients with comorbidities and inpatients who are not admitted to the intensive care unit (ICU), including those with risk factors of drug-resistant Streptococcus pneumoniae. For treatment of ICU patients with severe CAP, it is recommended that fluoroquinolones be used in combination with a β-lactam. Recent studies also demonstrated a more rapid resolution of clinical symptoms with the use of highly potent respiratory fluoroquinolones. Discussion: Appropriate use of fluoroquinolone agents may shorten the duration of antimicrobial therapy and the length of hospital stay and contribute to the decreased development of resistance in patients with CAP. Adverse event profiles of these agents should be considered to facilitate the selection of an appropriate fluoroquinolone for appropriate CAP patients. Conclusion: The fluoroquinolone class, specifically those with adequate activity against respiratory pathogens, represents an important and convenient treatment option for patients with CAP.

Original languageEnglish (US)
Pages (from-to)378-388
Number of pages11
JournalInternational Journal of Clinical Practice
Volume64
Issue number3
DOIs
StatePublished - Feb 2010

Fingerprint

Fluoroquinolones
Pneumonia
Therapeutics
Intensive Care Units
Length of Stay
Guidelines
Lactams
Levofloxacin
Bacteriology
Streptococcus pneumoniae
Comorbidity
Inpatients
Outpatients
Randomized Controlled Trials
Pharmacokinetics
Clinical Trials

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Fluoroquinolones in the management of community-acquired pneumonia. / Albertson, Timothy E; Dean, N. C.; El Solh, A. A.; Gotfried, M. H.; Kaplan, C.; Niederman, M. S.

In: International Journal of Clinical Practice, Vol. 64, No. 3, 02.2010, p. 378-388.

Research output: Contribution to journalArticle

Albertson, Timothy E ; Dean, N. C. ; El Solh, A. A. ; Gotfried, M. H. ; Kaplan, C. ; Niederman, M. S. / Fluoroquinolones in the management of community-acquired pneumonia. In: International Journal of Clinical Practice. 2010 ; Vol. 64, No. 3. pp. 378-388.
@article{11ff65a501d9456bb83dc841569a6e4f,
title = "Fluoroquinolones in the management of community-acquired pneumonia",
abstract = "Aims: Review of the current guidelines for the use of respiratory fluoroquinolones in the management of community-acquired pneumonia (CAP). Methods: Data were collected from recent clinical trials on fluoroquinolone therapy in patients with CAP and from updated recommendations of antimicrobial therapy in managing CAP, with a focus on current North American guidelines. Results: Randomised clinical trials of respiratory fluoroquinones (moxifloxacin, levofloxacin and gemifloxacin) in the treatment of CAP were identified and analysed. The bacteriology of CAP, and susceptibility rates, resistance rates and pharmacokinetic and pharmacodynamic properties of fluoroquinolones against causative pathogens in CAP, and adverse event profiles of these agents were described. Respiratory fluoroquinones have broad-spectrum antibacterial activities against common causative pathogens in CAP and provide an important treatment option as monotherapy for outpatients with comorbidities and inpatients who are not admitted to the intensive care unit (ICU), including those with risk factors of drug-resistant Streptococcus pneumoniae. For treatment of ICU patients with severe CAP, it is recommended that fluoroquinolones be used in combination with a β-lactam. Recent studies also demonstrated a more rapid resolution of clinical symptoms with the use of highly potent respiratory fluoroquinolones. Discussion: Appropriate use of fluoroquinolone agents may shorten the duration of antimicrobial therapy and the length of hospital stay and contribute to the decreased development of resistance in patients with CAP. Adverse event profiles of these agents should be considered to facilitate the selection of an appropriate fluoroquinolone for appropriate CAP patients. Conclusion: The fluoroquinolone class, specifically those with adequate activity against respiratory pathogens, represents an important and convenient treatment option for patients with CAP.",
author = "Albertson, {Timothy E} and Dean, {N. C.} and {El Solh}, {A. A.} and Gotfried, {M. H.} and C. Kaplan and Niederman, {M. S.}",
year = "2010",
month = "2",
doi = "10.1111/j.1742-1241.2009.02239.x",
language = "English (US)",
volume = "64",
pages = "378--388",
journal = "International Journal of Clinical Practice",
issn = "1368-5031",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Fluoroquinolones in the management of community-acquired pneumonia

AU - Albertson, Timothy E

AU - Dean, N. C.

AU - El Solh, A. A.

AU - Gotfried, M. H.

AU - Kaplan, C.

AU - Niederman, M. S.

PY - 2010/2

Y1 - 2010/2

N2 - Aims: Review of the current guidelines for the use of respiratory fluoroquinolones in the management of community-acquired pneumonia (CAP). Methods: Data were collected from recent clinical trials on fluoroquinolone therapy in patients with CAP and from updated recommendations of antimicrobial therapy in managing CAP, with a focus on current North American guidelines. Results: Randomised clinical trials of respiratory fluoroquinones (moxifloxacin, levofloxacin and gemifloxacin) in the treatment of CAP were identified and analysed. The bacteriology of CAP, and susceptibility rates, resistance rates and pharmacokinetic and pharmacodynamic properties of fluoroquinolones against causative pathogens in CAP, and adverse event profiles of these agents were described. Respiratory fluoroquinones have broad-spectrum antibacterial activities against common causative pathogens in CAP and provide an important treatment option as monotherapy for outpatients with comorbidities and inpatients who are not admitted to the intensive care unit (ICU), including those with risk factors of drug-resistant Streptococcus pneumoniae. For treatment of ICU patients with severe CAP, it is recommended that fluoroquinolones be used in combination with a β-lactam. Recent studies also demonstrated a more rapid resolution of clinical symptoms with the use of highly potent respiratory fluoroquinolones. Discussion: Appropriate use of fluoroquinolone agents may shorten the duration of antimicrobial therapy and the length of hospital stay and contribute to the decreased development of resistance in patients with CAP. Adverse event profiles of these agents should be considered to facilitate the selection of an appropriate fluoroquinolone for appropriate CAP patients. Conclusion: The fluoroquinolone class, specifically those with adequate activity against respiratory pathogens, represents an important and convenient treatment option for patients with CAP.

AB - Aims: Review of the current guidelines for the use of respiratory fluoroquinolones in the management of community-acquired pneumonia (CAP). Methods: Data were collected from recent clinical trials on fluoroquinolone therapy in patients with CAP and from updated recommendations of antimicrobial therapy in managing CAP, with a focus on current North American guidelines. Results: Randomised clinical trials of respiratory fluoroquinones (moxifloxacin, levofloxacin and gemifloxacin) in the treatment of CAP were identified and analysed. The bacteriology of CAP, and susceptibility rates, resistance rates and pharmacokinetic and pharmacodynamic properties of fluoroquinolones against causative pathogens in CAP, and adverse event profiles of these agents were described. Respiratory fluoroquinones have broad-spectrum antibacterial activities against common causative pathogens in CAP and provide an important treatment option as monotherapy for outpatients with comorbidities and inpatients who are not admitted to the intensive care unit (ICU), including those with risk factors of drug-resistant Streptococcus pneumoniae. For treatment of ICU patients with severe CAP, it is recommended that fluoroquinolones be used in combination with a β-lactam. Recent studies also demonstrated a more rapid resolution of clinical symptoms with the use of highly potent respiratory fluoroquinolones. Discussion: Appropriate use of fluoroquinolone agents may shorten the duration of antimicrobial therapy and the length of hospital stay and contribute to the decreased development of resistance in patients with CAP. Adverse event profiles of these agents should be considered to facilitate the selection of an appropriate fluoroquinolone for appropriate CAP patients. Conclusion: The fluoroquinolone class, specifically those with adequate activity against respiratory pathogens, represents an important and convenient treatment option for patients with CAP.

UR - http://www.scopus.com/inward/record.url?scp=74349124509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74349124509&partnerID=8YFLogxK

U2 - 10.1111/j.1742-1241.2009.02239.x

DO - 10.1111/j.1742-1241.2009.02239.x

M3 - Article

VL - 64

SP - 378

EP - 388

JO - International Journal of Clinical Practice

JF - International Journal of Clinical Practice

SN - 1368-5031

IS - 3

ER -